Viiv Healthcare releases positive new data on Juluca

3 April 2019

ViiV Healthcare today revealed new data from its SWORD studies, demonstrating that Juluca (dolutegravir/rilpivirine), the first two-drug regimen, once-daily, single-pill for HIV, maintains HIV viral suppression at 148-weeks.

Majority-owned by UK pharma major GlaxoSmithKline (LSE: GSK) ViiV Healthcare said three year results from the SWORD 1 and 2 studies showed that 84% (432/513) of participants who switched from their current three- or four-drug antiretroviral regimen to a 2-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (developed by Johnson & Johnson [NYSE: JNJ] subsidiary Janssen) maintained viral suppression (viral load ≤50 copies/mL).

These results were presented at the 25th Annual Conference of the British HIV Association (BHIVA) taking place April 2-5 in Bournemouth, UK.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK